Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.

Flicker L, Hopper JL, Larkins RG, Lichtenstein M, Buirski G, Wark JD

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA1 Jan 1997Cited by 22 (Europe PMC)

PMID9102059DOI10.1007/bf01623456PepBankPUB-09102059

Publisher page PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In elderly women with osteoporosis, factorial modelling associated calcitonin with an 11.5 +/- 4.7% loss of lumbar spine DEQCT BMD.
In plain wordsIn elderly women with osteoporosis, the factorial analysis linked calcitonin to lower spine bone density.
Peptide
Calcitonin-salmon
Outcome
DecreaseLumbar spine DEQCT BMD
Study
n: not reported in source
Comparator
no calcitonin in the factorial analysis
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 IU daily · intranasal · 2 yearsAs given in this study (human).
Measurements
Lumbar spine BMD loss
11.5%
factorial calcitonin estimate
Reported uncertainty
4.7%
factorial calcitonin estimate
P value
< 0.05
reported result
Source sentences
Summary
Modelling also revealed that calcitonin treatment was associated with a loss of 11.5 +/- 4.7% in DEQCT BMD at the lumbar spine and a loss of 3.7 +/- 1.8% in DXA BMD at the proximal femur (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This study used a randomized, 2 x 2 factorial design to evaluate over 2 years the effect of intranasal salmon calcitonin and intramuscular nandrolone decanoate on bone mass in elderly women with established osteoporosis.
Summary · context
Women were assigned to one of four groups: (1) daily placebo nasal spray, (2) 400 IU intranasal calcitonin daily, (3) 20 intramuscular injections of 50 mg nandrolone decanoate (given as two courses of 10 injections) plus placebo nasal spray, or (4) 20 injections of 50 mg nandrolone decanoate plus 40…
Summary · context
All subjects received 1000 mg calcium supplementation daily.
Report a problemFND-0910205902
02HumanRandomized controlled trialEfficacy outcome
In elderly women with osteoporosis, factorial modelling associated calcitonin with a 3.7 +/- 1.8% loss of proximal femur DXA BMD.
In plain wordsIn elderly women with osteoporosis, the factorial analysis linked calcitonin to lower upper thigh bone density.
Peptide
Calcitonin-salmon
Outcome
DecreaseProximal femur DXA BMD
Study
n: not reported in source
Comparator
no calcitonin in the factorial analysis
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 IU daily · intranasal · 2 yearsAs given in this study (human).
Measurements
Proximal femur BMD loss
3.7%
factorial calcitonin estimate
Reported uncertainty
1.8%
factorial calcitonin estimate
P value
< 0.05
reported result
Source sentences
Summary
Modelling also revealed that calcitonin treatment was associated with a loss of 11.5 +/- 4.7% in DEQCT BMD at the lumbar spine and a loss of 3.7 +/- 1.8% in DXA BMD at the proximal femur (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
This study used a randomized, 2 x 2 factorial design to evaluate over 2 years the effect of intranasal salmon calcitonin and intramuscular nandrolone decanoate on bone mass in elderly women with established osteoporosis.
Summary · context
Women were assigned to one of four groups: (1) daily placebo nasal spray, (2) 400 IU intranasal calcitonin daily, (3) 20 intramuscular injections of 50 mg nandrolone decanoate (given as two courses of 10 injections) plus placebo nasal spray, or (4) 20 injections of 50 mg nandrolone decanoate plus 40…
Summary · context
All subjects received 1000 mg calcium supplementation daily.
Report a problemFND-0910205903
03HumanNon-randomized trialEfficacy outcome
In elderly women with osteoporosis, calcitonin increased lumbar spine DXA bone mineral content by 5.0 +/- 1.9% from baseline.
In plain wordsIn elderly women with osteoporosis, spine bone mineral content increased during calcitonin treatment.
Peptide
Calcitonin-salmon
Outcome
IncreaseLumbar spine DXA BMC
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 IU daily · intranasal · 2 yearsAs given in this study (human).
Measurements
Lumbar spine BMC change
5%
calcitonin
Standard error
1.9%
calcitonin
Source sentences
Summary
Significant positive changes from baseline in DXA BMC at the lumbar spine were observed over 2 years in the calcitonin group (5.0 +/- 1.9%, mean +/- SE)
2 context sentences(design, population, supporting numbers)
Summary · context
This study used a randomized, 2 x 2 factorial design to evaluate over 2 years the effect of intranasal salmon calcitonin and intramuscular nandrolone decanoate on bone mass in elderly women with established osteoporosis.
Summary · context
All subjects received 1000 mg calcium supplementation daily.
Report a problemFND-0910205901

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.